My 10-year-old son, Cylus, was diagnosed with High Risk MYCN amplified Neuroblastoma in 2025. Within a year, his condition worsened drastically. He lost his ability to walk, his potential to have children, his hearing, and the function of his face, limbs, and bowels. Tragically, Cylus passed away at just 10 years old in March 2026. This experience has highlighted the critical need for more effective treatments and research for Neuroblastoma. We currently face a dire situation where limited treatment options come with devastating lifelong side effects and an increased risk of secondary cancers.

Childhood cancer research receives only 4% of federal funding, a woefully inadequate amount given the severity and impact of these diseases on our most vulnerable population. Neuroblastoma, a cancer that primarily affects infants and young children, is in desperate need of more research to enhance treatment options and reduce the harsh consequences currently faced by young patients.

Increasing the funding allocation from 4% to 8% is essential for significant advancements in treatments, specifically for underserved childhood cancers like Neuroblastoma. With more resources, we can invest in innovative research to discover new treatments that are less toxic and more effective. This increased funding could also support the development of targeted therapies that could improve survival rates and quality of life for children diagnosed with Neuroblastoma.

Let's stand together to advocate for our children, who deserve the chance for a healthier future. No more families should endure the loss and suffering we experienced with Cylus. By signing this petition, you are helping to push for necessary changes in the allocation of federal funds to research pediatric cancers. Let's ensure that our children have a fighting chance by advancing Neuroblastoma research and securing better health outcomes for the youngest among us. Sign this petition and be a part of the change that our children desperately need.